Tourmaline Bio, Inc. (TRML)

Tourmaline Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-88.47	-73.21	-42.12	-19.7	-0.9
Depreciation & Amortization	0.04	0.04	0.03	0.01	-
Asset Writedown & Restructuring Costs	-	-	8.82	12.13	-
Loss (Gain) From Sale of Investments	-7.12	-7.68	-0.54	-	-
Stock-Based Compensation	8.16	6.59	5.77	0.2	-
Other Operating Activities	0.16	0.15	0.12	0.02	-
Change in Accounts Payable	0.51	2.44	-0.04	0.19	0.78
Change in Other Net Operating Assets	0.44	-5.59	-0.12	0.71	0.13
Operating Cash Flow	-86.28	-77.26	-28.08	-6.46	-
Capital Expenditures	-0.03	-0.01	-0.06	-0.07	-
Sale (Purchase) of Intangibles	-	-	-	-5	-
Investment in Securities	46.96	-194.3	3.9	-	-
Investing Cash Flow	46.94	-194.31	3.84	-5.07	-
Short-Term Debt Issued	-	-	-	0.25	-
Total Debt Issued	-	-	-	0.25	0.6
Short-Term Debt Repaid	-	-	-	-0.4	-
Total Debt Repaid	-	-	-	-0.4	-
Net Debt Issued (Repaid)	-	-	-	-0.15	0.6
Issuance of Common Stock	0.62	161.35	0.14	-	-
Repurchase of Common Stock	-0.01	-0	-	-	-
Other Financing Activities	-	-	64.75	-	-
Financing Cash Flow	0.61	161.35	156.72	19.85	0.6
Net Cash Flow	-38.73	-110.22	132.48	8.32	0.6
Free Cash Flow	-86.3	-77.27	-28.14	-6.53	-
Free Cash Flow Per Share	-3.35	-3.05	-5.93	-7.44	-
Levered Free Cash Flow	-53.32	-50.17	-24.92	-16.26	-
Unlevered Free Cash Flow	-53.32	-50.17	-24.92	-16.26	-
Change in Working Capital	0.96	-3.15	-0.17	0.9	0.9

Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q